PFE - Pfizer Inc.
NYSE
->
Healthcare
->
Drug Manufacturers—General
New York,
United States
Type: Equity
PFE price evolution
PFE
| (in millions $) | 31 Jan 2024 | 2 Aug 2023 | 2 May 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2853 | $3148 | $2632 | $2166 |
| Short term investments | $9837 | $41033 | $42153 | $17806 |
| Net receivables | $11177 | $13425 | $12305 | $12305 |
| Inventory | $10189 | $10310 | $9541 | $9541 |
| Total current assets | $43333 | $73347 | $50078 | $50078 |
| Long term investments | $15368 | $14239 | $15066 | $14743 |
| Property, plant & equipment | $18940 | $17488 | $17052 | $17052 |
| Goodwill & intangible assets | $132683 | $91751 | $92978 | $93478 |
| Total noncurrent assets | $183168 | $141009 | $146821 | $145539 |
| Total investments | $25205 | $55272 | $57219 | $32549 |
| Total assets | $226501 | $220168 | $195617 | $195617 |
| Current liabilities | ||||
| Accounts payable | $6710 | $6081 | $6123 | $6123 |
| Deferred revenue | $2700 | $2204 | $1286 | $1750 |
| Short long term debt | $10350 | $2548 | $3985 | $4188 |
| Total current liabilities | $47794 | $34647 | $36562 | $36562 |
| Long term debt | $61538 | $61356 | $31704 | $31704 |
| Total noncurrent liabilities | $89419 | $86681 | $86228 | $57819 |
| Total debt | $71888 | $63596 | $65341 | $35892 |
| Total liabilities | $137213 | $121149 | $94647 | $94381 |
| Shareholders' equity | ||||
| Retained earnings | $118353 | $128796 | $131102 | $131102 |
| Other shareholder equity | -$7961 | -$7990 | -$8141 | -$8289 |
| Total shareholder equity | $89014 | $96934 | $99019 | $100970 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2853 | $416 | $1944 | $1784 |
| Short term investments | $9837 | $22316 | $29125 | $10437 |
| Net receivables | $11177 | $10952 | $11479 | $7930 |
| Inventory | $10189 | $8981 | $9059 | $8046 |
| Total current assets | $43333 | $51259 | $59693 | $35067 |
| Long term investments | $15368 | $15069 | $21526 | $20262 |
| Property, plant & equipment | $18940 | $19276 | $14882 | $13900 |
| Goodwill & intangible assets | $132683 | $94745 | $74354 | $78048 |
| Total noncurrent assets | $183168 | $145946 | $121783 | $119162 |
| Total investments | $25205 | $37385 | $50651 | $30699 |
| Total assets | $226501 | $197205 | $181476 | $154229 |
| Current liabilities | ||||
| Accounts payable | $6710 | $6809 | $5578 | $4309 |
| Deferred revenue | $2700 | $2520 | $3067 | |
| Short long term debt | $10350 | $2945 | $2241 | $2703 |
| Total current liabilities | $47794 | $42138 | $42671 | $25920 |
| Long term debt | $61538 | $32884 | $36195 | $37133 |
| Total noncurrent liabilities | $89419 | $59150 | $61342 | $64836 |
| Total debt | $71888 | $35829 | $38436 | $39836 |
| Total liabilities | $137213 | $101545 | $104013 | $90756 |
| Shareholders' equity | ||||
| Retained earnings | $118353 | $125656 | $103394 | $96770 |
| Other shareholder equity | -$7961 | -$8525 | -$5897 | -$11688 |
| Total shareholder equity | $89014 | $95661 | $77201 | $63238 |
| (in millions $) | 31 Jan 2024 | 2 Aug 2023 | 2 May 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14249 | $12734 | $18282 | |
| Cost of revenue | ||||
| Gross Profit | $7584 | $9332 | $13257 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $7709 | $7215 | $6571 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$795 | -$71 | $715 | |
| Interest expense | $2422 | $99 | -$313 | |
| Net income | ||||
| Net income | -$3369 | $2327 | $5543 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $58496 | $100330 | $81288 | $41908 |
| Cost of revenue | $34344 | $30821 | $8692 | |
| Gross Profit | $40707 | $65986 | $50467 | $33216 |
| Operating activities | ||||
| Research & development | $11428 | $13829 | $9405 | |
| Selling, general & administrative | $13677 | $12703 | $11615 | |
| Total operating expenses | $27899 | $31259 | $26156 | $25725 |
| Operating income | $34727 | $24311 | $7491 | |
| Income from continuing operations | ||||
| EBIT | $34700 | $23832 | $10093 | |
| Income tax expense | -$1115 | $3328 | $1852 | $477 |
| Interest expense | $1986 | |||
| Net income | ||||
| Net income | $2119 | $31372 | $21980 | $9616 |
| Income (for common shares) | $31372 | $21979 | $9616 | |
| (in millions $) | 31 Dec 2023 | 2 Aug 2023 | 2 May 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$3369 | $5543 | ||
| Operating activities | ||||
| Depreciation | $1670 | $1487 | ||
| Business acquisitions & disposals | -$43405 | |||
| Stock-based compensation | $121 | $105 | ||
| Total cash flows from operations | $5240 | $1212 | ||
| Investing activities | ||||
| Capital expenditures | -$1044 | -$1139 | ||
| Investments | $33438 | $4473 | ||
| Total cash flows from investing | -$10996 | -$22170 | $3315 | $3315 |
| Financing activities | ||||
| Dividends paid | -$2315 | -$4618 | -$2303 | -$2303 |
| Sale and purchase of stock | ||||
| Net borrowings | $7775 | -$32 | ||
| Total cash flows from financing | $5442 | $24403 | -$2771 | -$2771 |
| Effect of exchange rate | -$1 | -$7 | -$2 | -$2 |
| Change in cash and equivalents | -$316 | $2230 | $1754 | $1754 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $2119 | $31372 | $21980 | $9616 |
| Operating activities | ||||
| Depreciation | $6290 | $5064 | $5191 | $4777 |
| Business acquisitions & disposals | -$43430 | -$19037 | ||
| Stock-based compensation | $525 | $872 | $1182 | $756 |
| Total cash flows from operations | $8700 | $29267 | $32580 | $14403 |
| Investing activities | ||||
| Capital expenditures | -$3907 | -$3236 | -$2711 | -$2791 |
| Investments | $15239 | $6682 | -$19517 | -$1672 |
| Total cash flows from investing | -$32278 | -$15783 | -$22546 | -$4271 |
| Financing activities | ||||
| Dividends paid | -$9247 | -$8983 | -$8729 | -$8440 |
| Sale and purchase of stock | -$2000 | $425 | ||
| Net borrowings | $35945 | -$3516 | -$1103 | -$12755 |
| Total cash flows from financing | $26066 | -$14834 | -$9816 | -$9649 |
| Effect of exchange rate | -$40 | -$165 | -$59 | -$8 |
| Change in cash and equivalents | $2448 | -$1515 | $159 | $475 |
News
|
13 Best Ethical Companies to Invest in 2024
Insider Monkey via Yahoo Finance
24 Apr 2024
|
|
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown -...
Benzinga
23 Apr 2024
|
|
10 Best Performing Biotech ETFs in 2024
Insider Monkey via Yahoo Finance
22 Apr 2024
|
|
EU regulators approve Pfizer antibiotic Emblaveo (NYSE:PFE)
Seeking Alpha
22 Apr 2024
|
|
11 Best Low Price Pharma Stocks To Invest In
Insider Monkey via Yahoo Finance
21 Apr 2024
|
|
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Zacks via Yahoo Finance
19 Apr 2024
|
|
Big pharma: cautious optimism ahead of earnings season - analysts
Proactive Investors
18 Apr 2024
|
|
Pfizer-Connect Biopharma deal for inflammatory drug ends
Seeking Alpha
17 Apr 2024
|
|
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
Benzinga via Yahoo Finance
16 Apr 2024
|
|
A Win for the SEC on Shadow Trading. Now What?
The National Law Review
15 Apr 2024
|
Fundamentals
| Market cap | $148.60B |
|---|---|
| Enterprise value | $217.64B |
| Shares outstanding | 5.65B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -37.06% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 1.53 |
| Book/Share | 17.18 |
| Cash/Share | 0.51 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.54 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.91 |
| Quick ratio | 0.69 |